The most effective approach to fight COVID-19 infection is prevention by targeted vaccines that prime the immune system prior to a first encounter with the virus. The BNT162b2 messenger RNA (mRNA) vaccine encoding the SARS-CoV-2 full length spike generates antibodies that prevent the entry of the virus into cells by blocking either ACE2–RBD binding interactions or spike-mediated membrane fusion [1]. The vaccine proved efficient in a large multinational trial, including 21,720 subjects vaccinated with BNT162b2.
